Trials / Unknown
UnknownNCT06200220
Patients Treated in Real Life With VEnetoclax for WAldenström Macroglobulinemia
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 45 (estimated)
- Sponsor
- Poitiers University Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
Waldenström macroglobulinemia (WM) is an incurable disease. BCL2 antagonist, an important anti-apoptosys molecule, is already approved for the treatment of chronic lymphocytic leukemia (CLL) and acute myeloid leukemia. Recently, a clinical trial including 32 patients with WM treated with Venetoclax showed an overall response rates of 84% and a major response rate of 81%. However, there is no in real life data, in the french population, of the efficiency of Venetoclax in WM. The aim of our multicentric retrospective study is to evaluate the efficiency and tolerance of Venetoclax in WM.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Venetoclax | Observational study |
Timeline
- Start date
- 2023-12-28
- Primary completion
- 2023-12-28
- Completion
- 2025-12-01
- First posted
- 2024-01-10
- Last updated
- 2024-01-10
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT06200220. Inclusion in this directory is not an endorsement.